相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study
Lloyd Mayer et al.
GUT (2014)
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
Severine Vermeire et al.
LANCET (2014)
Vercirnon for the treatment of Crohn's disease
Kristen O. Arseneau et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Inhibition of Leukocyte Trafficking in Inflammatory Bowel Disease
Fabio Cominelli
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn's Disease
Satish Keshav et al.
PLOS ONE (2013)
Fatal PML associated with efalizumab therapy Insights into integrin αLβ2 in JC virus control
N. Schwab et al.
NEUROLOGY (2012)
Efalizumab, a Human Monoclonal Anti-CD11a Antibody, in the Treatment of Moderate to Severe Crohn's Disease: An Open-Label Pilot Study
Dustin G. James et al.
DIGESTIVE DISEASES AND SCIENCES (2011)
Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody
N. Pullen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study
Brian G. Feagan et al.
GASTROENTEROLOGY (2008)
Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE trial
Stephan R. Targan et al.
GASTROENTEROLOGY (2007)
Antisense therapy of MAdCAM-1 for trinitrobenzenesulfonic acid-induced murine colitis
Akira Goto et al.
INFLAMMATORY BOWEL DISEASES (2006)
A Phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis
SJH Van Deventer et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial
PB Miner et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Natalizumab induction and maintenance therapy for Crohn's disease
WJ Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Brief report - Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
G Van Assche et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis
P Miner et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis
SJH van Deventer et al.
GUT (2004)
Natalizumab for active Crohn's disease.
S Ghosh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease
BR Yacyshyn et al.
GUT (2002)
Involvement of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in the pathogenesis of granulomatous colitis in rats
R Hokari et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2001)
Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease
S Schreiber et al.
GASTROENTEROLOGY (2001)
Intercellular adhesion molecule-1 (ICAM-1) deficiency protects mice against severe forms of experimentally induced colitis
F Bendjelloul et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2000)
分享论文
